Preliminary results from a Phase 1 study offer evidence that a combination of pegylated arginine deiminase plus pemetrexed and cisplatin chemotherapy can disrupt mesothelioma cell growth. The results were announced in November by the Polaris Group, a biopharmaceutical company engaged in research and development of protein drugs to treat mesothelioma and other debilitating diseases. The